Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy

Author(s): Li Wang, Min Yao, Wenjie Zheng, Miao Fang, Mengna Wu, Jianying Sun, Zhizhen Dong*, Dengfu Yao*.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 19 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Human insulin-like growth factor (IGF) axis affects the molecular pathogenesis of hepatocellular carcinoma (HCC), especially in the abnormality of hepatic IGF-I receptor (IGF-IR) or IGF-II expression as a key molecule in hepatocarcinogenesis. However, the over-expression of hepatic IGFIR is associated with HCC progression with largely unknown mechanisms. The IGF-IR as one key molecule of the IGF signal pathway plays an important role in the hepatocyte malignant transformation. Attaching importance to IGF-IR might improve the prognostic or the therapeutic technique of HCC. This article reviews IGF-IR alteration during HCC development, and the effects of silencing IGF-IR gene by specific short hairpin RNA on the inhibition of cell proliferation in vitro or HCC xenograft growth in vivo to elucidate it as a novel molecular-targeted therapy for HCC.

Keywords: Hepatocellular carcinoma, insulin-like growth factor-I receptor, molecular targeted, gene therapy, gene amplification, xenograft tumor, cell proliferation.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 4
Year: 2019
Page: [272 - 280]
Pages: 9
DOI: 10.2174/1389557518666181025151608
Price: $58

Article Metrics

PDF: 8